$7.99
0.87% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US64049M2098
Symbol
NEO

NeoGenomics, Inc. Stock price

$7.99
-1.59 16.60% 1M
-7.37 47.98% 6M
-8.49 51.52% YTD
-6.92 46.41% 1Y
-0.80 9.10% 3Y
-20.07 71.53% 5Y
+2.82 54.55% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.07 0.87%
ISIN
US64049M2098
Symbol
NEO
Sector

Key metrics

Market capitalization $1.03b
Enterprise Value $1.27b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.90
P/S ratio (TTM) P/S ratio 1.53
P/B ratio (TTM) P/B ratio 1.15
Revenue growth (TTM) Revenue growth 10.10%
Revenue (TTM) Revenue $672.36m
EBIT (operating result TTM) EBIT $-80.72m
Free Cash Flow (TTM) Free Cash Flow $-32.37m
Cash position $358.08m
EPS (TTM) EPS $-0.61
P/E forward negative
P/S forward 1.38
EV/Sales forward 1.71
Short interest 5.10%
Show more

Is NeoGenomics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

NeoGenomics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a NeoGenomics, Inc. forecast:

9x Buy
56%
7x Hold
44%

Analyst Opinions

16 Analysts have issued a NeoGenomics, Inc. forecast:

Buy
56%
Hold
44%

Financial data from NeoGenomics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
672 672
10% 10%
100%
- Direct Costs 393 393
5% 5%
58%
279 279
19% 19%
42%
- Selling and Administrative Expenses 254 254
12% 12%
38%
- Research and Development Expense 34 34
22% 22%
5%
-8.72 -8.72
54% 54%
-1%
- Depreciation and Amortization 72 72
4% 4%
11%
EBIT (Operating Income) EBIT -81 -81
15% 15%
-12%
Net Profit -78 -78
8% 8%
-12%

In millions USD.

Don't miss a Thing! We will send you all news about NeoGenomics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

NeoGenomics, Inc. Stock News

Neutral
Business Wire
about 17 hours ago
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the William Blair Growth Stock Conference in Chicago and the Jefferies Global Healthcare Conference in New York.
Positive
MarketBeat
15 days ago
Those subscribing to a momentum investing strategy tend to believe that stocks experiencing price increases tend to rally, so long as both internal and external conditions don't change. Of course, no rally can continue forever, so investors may measure momentum across different timeframes.
Neutral
Business Wire
20 days ago
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics has paid off in full the remaining $201.25 million in principal amount outstanding of its 1.25% Convertible Senior Notes.
More NeoGenomics, Inc. News

Company Profile

NeoGenomics, Inc. is a clinical laboratory company, which specializes in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Head office United States
CEO Anthony Zook
Employees 2,200
Founded 1998
Website www.neogenomics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today